Finance-Funding

51. 2018 Likely A Banner Year For IPOs 2/7/2018

    2018 will be a good year for IPOs and for financing. Rounds are larger and non-traditional investors are turning to life sciences.

52. The Art Of Leadership 2/7/2018

    Former Pfizer exec and current partner at VC firm Polaris Partners Amy Schulman talks about what it takes to lead a pharma startup.

53. Recurring Mistakes (And Remedies) For Life Sciences M&As 1/9/2018

    Two members of a specialized life sciences investment banking group provide a list of avoidable missteps in M&A transactions and their respective remedies.

54. Not a Bad Year, After All 1/9/2018

    Peter Meath, who heads the Life Science Group at J.P. Morgan’s Commercial Banking business, offers advice to novice entrepreneurs for turning a company’s novel science into a viable business.

55. Investors Drumming Up New Solutions To The Industry's Real Estate Crunch 10/12/2017

    Investors are recognizing life sciences real estate as a valuable specialty asset class. In fact, it’s a trend gaining momentum as major real estate investment trusts (REITs) and entrepreneurial investors alike create new homes for life sciences activities.

56. Diversification Relieves Funding Pressure For Small Pharma 10/10/2017

    Chronic pressure is a way of life for those starting pharmaceutical companies. It’s a life filled with rounds of funding, investor demands, performance deadlines, and possible compound failures. But what if the technology owned by a startup drug discovery company was suddenly in demand by some of the world’s largest food and beverage corporations? What if that opportunity gives you the flexibility and time to conduct your research on your own timetable?

57. Lessons In Collaborating With Big Pharma 9/8/2017

    Any small biopharma knows the importance of collaborating or partnering with larger companies and academic institutions. But where do you start, and who should be involved? And what kind of risk should you take on?

58. Government Funding And Technology: The Right Ticket For Small Pharma 8/9/2017

    Soligenix is a late-stage biopharmaceutical company focused on rare diseases. The company’s president and CEO discusses how government grants and contracts can be one way to help fund research.

59. New Hampshire: A Biotech Microhub 8/9/2017

    As the biotech sector in the U.S. continues to grow, it is doing so not just in hubs, but in smaller places like New Hampshire — where some of the state’s biopharma entrepreneurs say: “Smaller is better.”

60. How A Biotech Startup Networked Through The Valley Of Death 7/7/2017

    We also sold our antibody drug candidate to Novartis in 2014 for another $5 million. We did everything we could to survive.